ArticleAnnals of the rheumatic diseases2021
Pathogenic
Article in Annals of the rheumatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.Arthritis & rheumatology (Hoboken, N.J.) · 2026Guideline
- Vacuolated Marrow Cytopenias from Copper Deficiency toInternational journal of molecular sciences · 2025Pooled it
- Pulmonary manifestations in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: a systematic review.Rheumatology international · 2023Pooled it
- SomaticBlood neoplasia · 2026Article
- VEXAS syndrome: a comprehensive clinicopathologic and genetic analysis of a predominantly Indian cohort.Journal of hematopathology · 2026Article
- What should neurologists expect to observe in relapsing polychondritis and VEXAS?Frontiers in immunology · 2026Review
- VEXAS syndrome.International journal of hematology · 2025Review
- Prevalence and outcome of VEXAS syndrome in unrelated hematopoietic cell transplantation for bone marrow failure.Clinical and experimental medicine · 2025Article
- Neurological manifestations in patients with VEXAS syndrome.Journal of neurology · 2025Article
- Clinical Challenges of Emerging Acquired Autoinflammatory Diseases, Including VEXAS Syndrome.Internal medicine (Tokyo, Japan) · 2025Review
- Case Report: Diagnostic challenges in VEXAS syndrome with novel ultrastructural lung findings: IgG4-RD and vasculitis as relevant differential diagnoses.Frontiers in immunology · 2025Article
- Relapsing Polychondritis With Palmoplantar Pustulosis: A Case Report.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2025Article
- VEXAS Syndrome: A Comprehensive Review of Current Therapeutic Strategies and Emerging Treatments.Journal of clinical medicine · 2024Review
- Clinical evaluation of droplet digital pcr for suspected ascites infection in patients with liver cirrhosis.Hepatology international · 2024Article
- VEXAS syndrome as a cause for multifocal, relapsing head and neck inflammation.Clinical case reports · 2024Article
- [The most frequent febrile syndromes and autoinflammatory diseases in adulthood].Zeitschrift fur Rheumatologie · 2024Review
- Relapsing polychondritis: clinical updates and new differential diagnoses.Nature reviews. Rheumatology · 2024Review
- [Macrocytic anemia and polychondritis: VEXAS syndrome].Zeitschrift fur Rheumatologie · 2024Article
- Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu's arteritis, ANCA-associated vasculitis and giant cell arteritis.Annals of the rheumatic diseases · 2024Article
- A novel XNA-based Luminex assay to detect UBA1 somatic mutations associated with VEXAS syndrome.Practical laboratory medicine · 2024Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine clinical and genetic features of individuals with relapsing polychondritis (RP) likely caused by pathogenic somatic variants in ubiquitin-like modifier activating enzyme 1 (
methodsFourteen patients with RP who met the Damiani and Levine criteria were recruited (12 men, 2 women; median onset age (IQR) 72.1 years (67.1-78.0)). Sanger sequencing of
results
conclusionsGenetic screening for pathogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.